baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Anthera Pharmaceuticals, Inc./ US03674U3005 /

10/10/2024 5:00:02 PM	Chg. -	Volume	Bid-	Ask-	High	Low
0.0001USD	-	850 Turnover: .0787	-Bid Size: -	-Ask Size: -	0.0001	0.0001

GlobeNewswire 11/23/2021 Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VIS...

GlobeNewswire 8/2/2021 Oyster Point Pharma Announces New Chairperson Appointment to Board of Directors

GlobeNewswire 9/10/2020 Opthea Appoints US-Based Non-Executive Director

GlobeNewswire 7/8/2020 Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regul...

GlobeNewswire 5/16/2019 Geron Continues to Build Senior Leadership of Its Development Team

GlobeNewswire 1/22/2019 Apollomics, Inc. Strengthens Leadership with Key Hires

GlobeNewswire 8/31/2018 Report: Developing Opportunities within Anthera Pharmaceuticals, NRG Energy, Antares Pharma, El Poll...

GlobeNewswire 8/22/2018 Global Oral Proteins and Peptides Market 2018-2030 - Current Market Landscape of Orally Administrabl...

GlobeNewswire 6/27/2018 Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading...

GlobeNewswire 5/30/2018 AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer

GlobeNewswire 5/16/2018 Oral Proteins and Peptides Market, 2030

GlobeNewswire 5/4/2018 New Research: Key Drivers of Growth for Global Medical REIT, DXP Enterprises, SJW, FTI Consulting, A...

GlobeNewswire 3/19/2018 Research Report Identifies Anthera Pharmaceuticals, Hancock Holding, MKS Instruments, Second Sight M...

GlobeNewswire 3/13/2018 World Novel Drugs and Smart Devices for Respiratory Disorders Market, 2030

GlobeNewswire 3/12/2018 Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura

GlobeNewswire 3/7/2018 Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference

GlobeNewswire 3/6/2018 Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria

GlobeNewswire 3/5/2018 Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Fin...

GlobeNewswire 2/8/2018 Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Hu...

GlobeNewswire 2/5/2018 Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura

GlobeNewswire 1/25/2018 Anthera Receives Positive Nasdaq Listing Determination

GlobeNewswire 1/22/2018 Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinica...

GlobeNewswire 1/17/2018 Report: Exploring Fundamental Drivers Behind Anthera Pharmaceuticals, Alarm, Aptevo Therapeutics, Sh...

GlobeNewswire 1/9/2018 Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering

GlobeNewswire 1/8/2018 Anthera Pharmaceuticals Announces Results of Special Meeting of Stockholders

Anthera Pharmaceuticals, Inc./ US03674U3005 /

If you wish to receive reply to your feedback, please provide your email address.